Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage
Objective To analyze whether changes in serum 25‐hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE). Methods We performed an observational study of 80 patients with SLE included in a previous cross‐sectional study of 25(OH)...
Saved in:
Published in | Arthritis care & research (2010) Vol. 62; no. 8; pp. 1160 - 1165 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.08.2010
|
Subjects | |
Online Access | Get full text |
ISSN | 2151-464X 2151-4658 2151-4658 |
DOI | 10.1002/acr.20186 |
Cover
Abstract | Objective
To analyze whether changes in serum 25‐hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE).
Methods
We performed an observational study of 80 patients with SLE included in a previous cross‐sectional study of 25(OH)D, reassessed 2 years later. Oral vitamin D3 was recommended in those with low baseline 25(OH)D levels. The relationship between changes in 25(OH)D levels from baseline and changes in fatigue (measured by a 0–10 visual analog scale [VAS]), SLE activity (measured by the Systemic Lupus Erythematosus Disease Activity Index [SLEDAI]), and irreversible organ damage (measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) were analyzed.
Results
Sixty patients took vitamin D3. Mean 25(OH)D levels increased among all treated patients (P = 0.044), in those with baseline vitamin D levels <30 ng/ml (P < 0.001), and in those with baseline vitamin D levels <10 ng/ml (P = 0.005). Fifty‐seven patients (71%) still had 25(OH)D levels <30 ng/ml and 5 (6%) had 25(OH)D levels <10 ng/ml. Inverse significant correlations between 25(OH)D levels and the VAS (P = 0.001) and between changes in 25(OH)D levels and changes in the VAS in patients with baseline 25(OH)D levels <30 ng/ml (P = 0.017) were found. No significant correlations were seen between the variation of the SLEDAI or SDI values and the variation in 25(OH)D levels (P = 0.87 and P = 0.63, respectively).
Conclusion
Increasing 25(OH)D levels may have a beneficial effect on fatigue. Our results do not support any effects of increasing 25(OH)D levels on SLE severity, although they are limited by the insufficient 25(OH)D response to the recommended regimen of oral vitamin D3 replacement. |
---|---|
AbstractList | To analyze whether changes in serum 25-hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE).
We performed an observational study of 80 patients with SLE included in a previous cross-sectional study of 25(OH)D, reassessed 2 years later. Oral vitamin D(3) was recommended in those with low baseline 25(OH)D levels. The relationship between changes in 25(OH)D levels from baseline and changes in fatigue (measured by a 0-10 visual analog scale [VAS]), SLE activity (measured by the Systemic Lupus Erythematosus Disease Activity Index [SLEDAI]), and irreversible organ damage (measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) were analyzed.
Sixty patients took vitamin D(3). Mean 25(OH)D levels increased among all treated patients (P = 0.044), in those with baseline vitamin D levels <30 ng/ml (P < 0.001), and in those with baseline vitamin D levels <10 ng/ml (P = 0.005). Fifty-seven patients (71%) still had 25(OH)D levels <30 ng/ml and 5 (6%) had 25(OH)D levels <10 ng/ml. Inverse significant correlations between 25(OH)D levels and the VAS (P = 0.001) and between changes in 25(OH)D levels and changes in the VAS in patients with baseline 25(OH)D levels <30 ng/ml (P = 0.017) were found. No significant correlations were seen between the variation of the SLEDAI or SDI values and the variation in 25(OH)D levels (P = 0.87 and P = 0.63, respectively).
Increasing 25(OH)D levels may have a beneficial effect on fatigue. Our results do not support any effects of increasing 25(OH)D levels on SLE severity, although they are limited by the insufficient 25(OH)D response to the recommended regimen of oral vitamin D(3) replacement. Objective To analyze whether changes in serum 25‐hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE). Methods We performed an observational study of 80 patients with SLE included in a previous cross‐sectional study of 25(OH)D, reassessed 2 years later. Oral vitamin D3 was recommended in those with low baseline 25(OH)D levels. The relationship between changes in 25(OH)D levels from baseline and changes in fatigue (measured by a 0–10 visual analog scale [VAS]), SLE activity (measured by the Systemic Lupus Erythematosus Disease Activity Index [SLEDAI]), and irreversible organ damage (measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) were analyzed. Results Sixty patients took vitamin D3. Mean 25(OH)D levels increased among all treated patients (P = 0.044), in those with baseline vitamin D levels <30 ng/ml (P < 0.001), and in those with baseline vitamin D levels <10 ng/ml (P = 0.005). Fifty‐seven patients (71%) still had 25(OH)D levels <30 ng/ml and 5 (6%) had 25(OH)D levels <10 ng/ml. Inverse significant correlations between 25(OH)D levels and the VAS (P = 0.001) and between changes in 25(OH)D levels and changes in the VAS in patients with baseline 25(OH)D levels <30 ng/ml (P = 0.017) were found. No significant correlations were seen between the variation of the SLEDAI or SDI values and the variation in 25(OH)D levels (P = 0.87 and P = 0.63, respectively). Conclusion Increasing 25(OH)D levels may have a beneficial effect on fatigue. Our results do not support any effects of increasing 25(OH)D levels on SLE severity, although they are limited by the insufficient 25(OH)D response to the recommended regimen of oral vitamin D3 replacement. To analyze whether changes in serum 25-hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE).OBJECTIVETo analyze whether changes in serum 25-hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE).We performed an observational study of 80 patients with SLE included in a previous cross-sectional study of 25(OH)D, reassessed 2 years later. Oral vitamin D(3) was recommended in those with low baseline 25(OH)D levels. The relationship between changes in 25(OH)D levels from baseline and changes in fatigue (measured by a 0-10 visual analog scale [VAS]), SLE activity (measured by the Systemic Lupus Erythematosus Disease Activity Index [SLEDAI]), and irreversible organ damage (measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) were analyzed.METHODSWe performed an observational study of 80 patients with SLE included in a previous cross-sectional study of 25(OH)D, reassessed 2 years later. Oral vitamin D(3) was recommended in those with low baseline 25(OH)D levels. The relationship between changes in 25(OH)D levels from baseline and changes in fatigue (measured by a 0-10 visual analog scale [VAS]), SLE activity (measured by the Systemic Lupus Erythematosus Disease Activity Index [SLEDAI]), and irreversible organ damage (measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) were analyzed.Sixty patients took vitamin D(3). Mean 25(OH)D levels increased among all treated patients (P = 0.044), in those with baseline vitamin D levels <30 ng/ml (P < 0.001), and in those with baseline vitamin D levels <10 ng/ml (P = 0.005). Fifty-seven patients (71%) still had 25(OH)D levels <30 ng/ml and 5 (6%) had 25(OH)D levels <10 ng/ml. Inverse significant correlations between 25(OH)D levels and the VAS (P = 0.001) and between changes in 25(OH)D levels and changes in the VAS in patients with baseline 25(OH)D levels <30 ng/ml (P = 0.017) were found. No significant correlations were seen between the variation of the SLEDAI or SDI values and the variation in 25(OH)D levels (P = 0.87 and P = 0.63, respectively).RESULTSSixty patients took vitamin D(3). Mean 25(OH)D levels increased among all treated patients (P = 0.044), in those with baseline vitamin D levels <30 ng/ml (P < 0.001), and in those with baseline vitamin D levels <10 ng/ml (P = 0.005). Fifty-seven patients (71%) still had 25(OH)D levels <30 ng/ml and 5 (6%) had 25(OH)D levels <10 ng/ml. Inverse significant correlations between 25(OH)D levels and the VAS (P = 0.001) and between changes in 25(OH)D levels and changes in the VAS in patients with baseline 25(OH)D levels <30 ng/ml (P = 0.017) were found. No significant correlations were seen between the variation of the SLEDAI or SDI values and the variation in 25(OH)D levels (P = 0.87 and P = 0.63, respectively).Increasing 25(OH)D levels may have a beneficial effect on fatigue. Our results do not support any effects of increasing 25(OH)D levels on SLE severity, although they are limited by the insufficient 25(OH)D response to the recommended regimen of oral vitamin D(3) replacement.CONCLUSIONIncreasing 25(OH)D levels may have a beneficial effect on fatigue. Our results do not support any effects of increasing 25(OH)D levels on SLE severity, although they are limited by the insufficient 25(OH)D response to the recommended regimen of oral vitamin D(3) replacement. |
Author | Gordo, Susana Olivares, Nerea Aguirre, Ciriaco Ruiz‐Irastorza, Guillermo Egurbide, Maria‐Victoria |
Author_xml | – sequence: 1 givenname: Guillermo surname: Ruiz‐Irastorza fullname: Ruiz‐Irastorza, Guillermo email: r.irastorza@euskalnet.net – sequence: 2 givenname: Susana surname: Gordo fullname: Gordo, Susana – sequence: 3 givenname: Nerea surname: Olivares fullname: Olivares, Nerea – sequence: 4 givenname: Maria‐Victoria surname: Egurbide fullname: Egurbide, Maria‐Victoria – sequence: 5 givenname: Ciriaco surname: Aguirre fullname: Aguirre, Ciriaco |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20235208$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kU9P3DAQxS0EKpRy4AtUvlVILDh21nF6Qwv9IyEhISr1Zjn2eNdV4iwZBxTx5WvYpYcK5jKj0e-9w3sfyW7sIxByXLCzgjF-buxwxlmh5A454MW8mJVyrnb_3eXvfXKE-IflEVwpUX8g-5xxMedMHZCnxcrEJSANkT6EZLq8L2kLD9C-_NYmBYgJ6WNIK4oTJuiCpe24HpHCMKUVdCb1OOJXeuU92Iz2kfosW45wSl1AMAjU2BSy_3RKTXTUmc4s4RPZ86ZFONruQ_Lr29Xd4sfs-ub7z8XF9cwKXspZVUrRNI2vgDXSWyZdUXnpgBlRg3eqqq2QTdlYI6VvLHDvTaFqLrxw9bx04pB82fiuh_5-BEy6C2ihbU2EfkRdlaoumapFJj9vybHpwOn1EDozTPo1rwycbwA79IgDeG1zaCn0MQ0mtLpg-rkUnUvRL6Vkxcl_ilfTt9it-2NoYXof1BeL243iL1-DnUE |
CitedBy_id | crossref_primary_10_1136_ard_2010_148494 crossref_primary_10_1371_journal_pgph_0002475 crossref_primary_10_1016_j_rbre_2017_08_001 crossref_primary_10_3899_jrheum_111594 crossref_primary_10_1016_j_lpm_2014_03_009 crossref_primary_10_1186_s13293_021_00358_3 crossref_primary_10_2174_1874312901812010226 crossref_primary_10_1177_0961203314559089 crossref_primary_10_1155_2017_7687053 crossref_primary_10_1016_j_medcle_2017_12_040 crossref_primary_10_1002_acr_20568 crossref_primary_10_1038_nrrheum_2013_71 crossref_primary_10_1177_0961203317706557 crossref_primary_10_1002_acr_22621 crossref_primary_10_1016_j_autrev_2012_07_007 crossref_primary_10_1016_j_reuma_2024_07_004 crossref_primary_10_1016_j_autrev_2017_09_011 crossref_primary_10_1371_journal_pone_0270569 crossref_primary_10_1097_BOR_0b013e32835cfc16 crossref_primary_10_4137_IMI_S40035 crossref_primary_10_1111_1756_185X_12489 crossref_primary_10_1016_j_reumae_2024_10_003 crossref_primary_10_1016_j_revmed_2011_11_010 crossref_primary_10_1016_j_bcp_2024_116417 crossref_primary_10_1093_rheumatology_kew212 crossref_primary_10_1136_annrheumdis_2016_209157 crossref_primary_10_4161_derm_20443 crossref_primary_10_1016_j_semarthrit_2010_07_009 crossref_primary_10_1002_acr_21840 crossref_primary_10_1017_S0029665111001613 crossref_primary_10_1051_mbcb_2020062 crossref_primary_10_4103_jioh_jioh_61_22 crossref_primary_10_1007_s00011_020_01337_x crossref_primary_10_1007_s10067_014_2530_5 crossref_primary_10_1002_acr_21839 crossref_primary_10_1007_s12016_013_8361_3 crossref_primary_10_3109_03009742_2012_697189 crossref_primary_10_1007_s10067_012_2021_5 crossref_primary_10_3390_nu12030789 crossref_primary_10_1016_j_rbr_2017_05_009 crossref_primary_10_1080_17482631_2019_1632111 crossref_primary_10_1016_j_autrev_2018_01_004 crossref_primary_10_1016_j_amjms_2019_04_020 crossref_primary_10_3390_ijms19082355 crossref_primary_10_1007_s00296_016_3497_0 crossref_primary_10_1136_jnnp_2014_308374 crossref_primary_10_1136_lupus_2014_000027 crossref_primary_10_1177_0961203311421798 crossref_primary_10_1177_1076029618786574 crossref_primary_10_3889_oamjms_2014_119 crossref_primary_10_3389_fimmu_2020_616483 crossref_primary_10_1038_s41584_023_00944_2 crossref_primary_10_1177_0961203318796293 crossref_primary_10_1007_s00198_017_4316_5 crossref_primary_10_1016_j_ejr_2011_07_004 crossref_primary_10_1016_j_lpm_2013_06_014 crossref_primary_10_1016_j_rbr_2014_09_008 crossref_primary_10_2217_ijr_12_78 crossref_primary_10_3389_fimmu_2023_1147447 crossref_primary_10_1016_j_ejr_2014_07_005 crossref_primary_10_1016_j_biopha_2020_110256 crossref_primary_10_1007_s11926_011_0188_4 crossref_primary_10_1186_ar3161 crossref_primary_10_3390_nu16020221 crossref_primary_10_1177_0961203311401457 crossref_primary_10_3389_fimmu_2015_00513 crossref_primary_10_3389_frph_2022_936810 crossref_primary_10_3892_etm_2018_6986 crossref_primary_10_1007_s13317_017_0101_x crossref_primary_10_1177_0961203314540966 crossref_primary_10_46497_ArchRheumatol_2022_8996 crossref_primary_10_1016_j_medcli_2017_12_007 crossref_primary_10_2217_ijr_12_4 crossref_primary_10_1016_j_autrev_2016_03_015 crossref_primary_10_1016_j_ejr_2020_08_005 crossref_primary_10_1007_s12026_017_8903_5 crossref_primary_10_1093_rheumatology_key398 crossref_primary_10_1177_0961203311425530 crossref_primary_10_1016_j_jcm_2011_06_006 crossref_primary_10_1016_j_yexmp_2023_104866 crossref_primary_10_1016_j_autrev_2017_11_004 crossref_primary_10_1016_j_medcli_2016_01_013 crossref_primary_10_1016_j_medcle_2016_06_033 crossref_primary_10_7759_cureus_25896 crossref_primary_10_1371_journal_pone_0055275 crossref_primary_10_3390_jcm10173996 crossref_primary_10_2217_nmt_11_59 crossref_primary_10_1007_s00296_010_1736_3 crossref_primary_10_1177_0961203316635289 crossref_primary_10_1586_eci_13_19 crossref_primary_10_2174_1874312901812010201 crossref_primary_10_1038_nrdp_2016_39 crossref_primary_10_1007_s12070_021_02913_1 crossref_primary_10_1016_S0151_9638_13_70142_X crossref_primary_10_1016_j_jaut_2016_06_010 crossref_primary_10_1016_j_rbre_2014_09_010 crossref_primary_10_1136_lupus_2020_000441 crossref_primary_10_1177_0961203314566636 crossref_primary_10_1186_s41927_021_00223_1 crossref_primary_10_3899_jrheum_180831 crossref_primary_10_1177_0961203314522338 crossref_primary_10_1002_art_37953 crossref_primary_10_3390_nu11102315 |
Cites_doi | 10.1097/BOR.0b013e32830a991b 10.1056/NEJMra070553 10.1007/s11926-008-0044-3 10.1373/clinchem.2004.040683 10.1016/j.autrev.2005.05.009 10.1093/rheumatology/ken121 10.1002/art.24785 10.1196/annals.1398.061 10.4049/jimmunol.179.3.1634 10.1177/0961203307085879 10.1093/rheumatology/ken394 10.1196/annals.1351.031 10.1097/MAJ.0b013e318134eeb6 10.1093/ajcn/75.4.611 10.1196/annals.1398.044 10.1093/ajcn/80.6.1717S 10.1016/j.atherosclerosis.2008.10.033 10.1001/archinte.168.15.1629 10.1002/art.1780400928 10.1002/art.23113 10.1136/bmj.326.7399.1124 10.1007/BF02207671 |
ContentType | Journal Article |
Copyright | Copyright © 2010 by the American College of Rheumatology |
Copyright_xml | – notice: Copyright © 2010 by the American College of Rheumatology |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1002/acr.20186 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2151-4658 |
EndPage | 1165 |
ExternalDocumentID | 20235208 10_1002_acr_20186 ACR20186 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Actelion – fundername: BIOEF |
GroupedDBID | .3N .GA .Y3 0R~ 10A 1OC 24P 31~ 33P 4.4 50Z 51W 51X 52N 52O 52P 52R 52S 52T 52W 52X 53G 5VS 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCUV ABIJN ABQWH ABXGK ACAHQ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADMGS ADOZA ADXAS ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BRXPI BY8 D-6 D-7 D-E D-F DCZOG DR2 DRFUL DRMAN DRSTM EBS EJD EMOBN F00 F01 F04 F5P FUBAC G-S GODZA H.X HF~ HGLYW HZ~ J0M J5H KBYEO LATKE LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N04 N05 NF~ O66 O9- P2P P2W P2X P2Z P4B P4D Q.N QB0 ROL SUPJJ TEORI UB1 V9Y W8V W99 WBKPD WHWMO WIK WOHZO WQJ WVDHM WXI WXSBR XG1 ZZTAW ~WT AAYXX ABJNI AEYWJ AGHNM AGYGG CITATION OVD AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c3246-7463bbbf7e0b6fc06d17f6de0a39efd879c36b4bca66fbce2ffa18923f3d954d3 |
IEDL.DBID | DR2 |
ISSN | 2151-464X 2151-4658 |
IngestDate | Fri Jul 11 11:59:24 EDT 2025 Mon Jul 21 06:01:45 EDT 2025 Tue Jul 01 01:37:17 EDT 2025 Thu Apr 24 22:54:55 EDT 2025 Wed Jan 22 16:26:40 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3246-7463bbbf7e0b6fc06d17f6de0a39efd879c36b4bca66fbce2ffa18923f3d954d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 20235208 |
PQID | 748940893 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_748940893 pubmed_primary_20235208 crossref_citationtrail_10_1002_acr_20186 crossref_primary_10_1002_acr_20186 wiley_primary_10_1002_acr_20186_ACR20186 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | August 2010 2010-08-00 2010-Aug 20100801 |
PublicationDateYYYYMMDD | 2010-08-01 |
PublicationDate_xml | – month: 08 year: 2010 text: August 2010 |
PublicationDecade | 2010 |
PublicationPlace | Hoboken, USA |
PublicationPlace_xml | – name: Hoboken, USA – name: United States |
PublicationTitle | Arthritis care & research (2010) |
PublicationTitleAlternate | Arthritis Care Res (Hoboken) |
PublicationYear | 2010 |
Publisher | John Wiley & Sons, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc |
References | 2007; 357 2007; 179 1997; 40 2004; 50 2000; 27 2003; 326 2002; 75 2006; 54 2009; 61 1995; 14 2008; 17 2008; 47 2007; 1109 2006; 5 2008; 10 2008; 335 2006; 1069 2001; 28 2008; 20 2008; 168 2004; 80 2007; 57 2009; 48 2009; 205 e_1_2_7_5_2 Martins DC (e_1_2_7_24_2) 2006; 54 e_1_2_7_4_2 Huisman AM (e_1_2_7_26_2) 2001; 28 e_1_2_7_3_2 e_1_2_7_2_2 Gladman DD (e_1_2_7_10_2) 2000; 27 e_1_2_7_8_2 e_1_2_7_7_2 e_1_2_7_6_2 e_1_2_7_19_2 e_1_2_7_18_2 e_1_2_7_17_2 e_1_2_7_16_2 e_1_2_7_15_2 e_1_2_7_14_2 e_1_2_7_13_2 e_1_2_7_12_2 e_1_2_7_11_2 e_1_2_7_27_2 Ward MM (e_1_2_7_9_2) 2000; 27 e_1_2_7_25_2 e_1_2_7_23_2 e_1_2_7_22_2 e_1_2_7_21_2 e_1_2_7_20_2 |
References_xml | – volume: 17 start-page: 6 year: 2008 end-page: 10 article-title: Vitamin D, immunity and lupus publication-title: Lupus – volume: 54 start-page: S431 issue: Suppl year: 2006 article-title: The threshold of vitamin D required for optimal immune regulation: implications for patients with lupus publication-title: Arthritis Rheum – volume: 1109 start-page: 385 year: 2007 end-page: 400 article-title: Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases publication-title: Ann N Y Acad Sci – volume: 28 start-page: 2535 year: 2001 end-page: 9 article-title: Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia publication-title: J Rheumatol – volume: 48 start-page: 210 year: 2009 end-page: 2 article-title: Vitamin D and autoimmune rheumatic diseases publication-title: Rheumatology (Oxford) – volume: 61 start-page: 1387 year: 2009 end-page: 95 article-title: 25‐hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus publication-title: Arthritis Rheum – volume: 10 start-page: 273 year: 2008 end-page: 80 article-title: The link between vitamin D deficiency and systemic lupus erythematosus publication-title: Curr Rheumatol Rep – volume: 326 start-page: 124 year: 2003 article-title: Iron supplementation for unexplained fatigue in non‐anaemic women: double blind randomised placebo controlled trial publication-title: BMJ – volume: 40 start-page: 1725 year: 1997 article-title: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus publication-title: Arthritis Rheum – volume: 20 start-page: 532 year: 2008 end-page: 7 article-title: Vitamin D in systemic lupus erythematosus publication-title: Curr Opin Rheumatol – volume: 1109 start-page: 550 year: 2007 end-page: 7 article-title: Anti‐vitamin D, vitamin D in SLE: preliminary results publication-title: Ann N Y Acad Sci – volume: 5 start-page: 114 year: 2006 end-page: 7 article-title: Vitamin D deficiency in systemic lupus erythematosus publication-title: Autoimmun Rev – volume: 57 start-page: 1348 year: 2007 end-page: 57 article-title: Measurement of fatigue in systemic lupus erythematosus: a systematic review publication-title: Arthritis Rheum – volume: 1069 start-page: 322 year: 2006 end-page: 45 article-title: Predicting and preventing autoimmunity, myth or reality? publication-title: Ann N Y Acad Sci – volume: 75 start-page: 611 year: 2002 end-page: 5 article-title: Vitamin D deficiency, muscle function, and falls in elderly people publication-title: Am J Clin Nutr – volume: 47 start-page: 920 year: 2008 end-page: 3 article-title: Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences publication-title: Rheumatology (Oxford) – volume: 50 start-page: 2195 year: 2004 end-page: 7 article-title: How accurate are assays for 25‐hydroxyvitamin D? Data from the International Vitamin D External Quality Assessment Scheme publication-title: Clin Chem – volume: 80 start-page: S1717 issue: Suppl year: 2004 end-page: 20 article-title: Vitamin D status, 1,25‐dihydroxyvitamin D3, and the immune system publication-title: Am J Clin Nutr – volume: 27 start-page: 373 year: 2000 end-page: 6 article-title: The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison publication-title: J Rheumatol – volume: 168 start-page: 1629 year: 2008 end-page: 37 article-title: 25‐hydroxyvitamin D levels and the risk of mortality in the general population publication-title: Arch Intern Med – volume: 27 start-page: 664 year: 2000 end-page: 70 article-title: Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus publication-title: J Rheumatol – volume: 357 start-page: 266 year: 2007 end-page: 81 article-title: Vitamin D deficiency publication-title: N Engl J Med – volume: 179 start-page: 1634 year: 2007 end-page: 47 article-title: Modulatory effects of 1,25‐dihydroxyvitamin D on human B cell differentiation publication-title: J Immunol – volume: 205 start-page: 255 year: 2009 end-page: 60 article-title: 25‐Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey publication-title: Atheroclerosis – volume: 14 start-page: 397 year: 1995 end-page: 400 article-title: Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25‐hydroxyvitamin D3 in patients with systemic lupus erythematosus publication-title: Clin Rheumatol – volume: 335 start-page: 99 year: 2008 end-page: 104 article-title: Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus publication-title: Am J Med Sci – volume: 27 start-page: 373 year: 2000 ident: e_1_2_7_10_2 article-title: The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison publication-title: J Rheumatol – ident: e_1_2_7_2_2 doi: 10.1097/BOR.0b013e32830a991b – ident: e_1_2_7_4_2 doi: 10.1056/NEJMra070553 – ident: e_1_2_7_6_2 doi: 10.1007/s11926-008-0044-3 – ident: e_1_2_7_12_2 doi: 10.1373/clinchem.2004.040683 – ident: e_1_2_7_14_2 doi: 10.1016/j.autrev.2005.05.009 – ident: e_1_2_7_7_2 doi: 10.1093/rheumatology/ken121 – ident: e_1_2_7_25_2 doi: 10.1002/art.24785 – ident: e_1_2_7_16_2 doi: 10.1196/annals.1398.061 – ident: e_1_2_7_15_2 doi: 10.4049/jimmunol.179.3.1634 – ident: e_1_2_7_23_2 doi: 10.1177/0961203307085879 – ident: e_1_2_7_5_2 doi: 10.1093/rheumatology/ken394 – ident: e_1_2_7_22_2 doi: 10.1196/annals.1351.031 – ident: e_1_2_7_18_2 doi: 10.1097/MAJ.0b013e318134eeb6 – volume: 27 start-page: 664 year: 2000 ident: e_1_2_7_9_2 article-title: Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus publication-title: J Rheumatol – volume: 54 start-page: S431 year: 2006 ident: e_1_2_7_24_2 article-title: The threshold of vitamin D required for optimal immune regulation: implications for patients with lupus publication-title: Arthritis Rheum – volume: 28 start-page: 2535 year: 2001 ident: e_1_2_7_26_2 article-title: Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia publication-title: J Rheumatol – ident: e_1_2_7_19_2 doi: 10.1093/ajcn/75.4.611 – ident: e_1_2_7_17_2 doi: 10.1196/annals.1398.044 – ident: e_1_2_7_21_2 doi: 10.1093/ajcn/80.6.1717S – ident: e_1_2_7_20_2 doi: 10.1016/j.atherosclerosis.2008.10.033 – ident: e_1_2_7_3_2 doi: 10.1001/archinte.168.15.1629 – ident: e_1_2_7_8_2 doi: 10.1002/art.1780400928 – ident: e_1_2_7_27_2 doi: 10.1002/art.23113 – ident: e_1_2_7_11_2 doi: 10.1136/bmj.326.7399.1124 – ident: e_1_2_7_13_2 doi: 10.1007/BF02207671 |
SSID | ssj0000328839 |
Score | 2.3441415 |
Snippet | Objective
To analyze whether changes in serum 25‐hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus... To analyze whether changes in serum 25-hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1160 |
SubjectTerms | Adult Cholecalciferol Cross-Sectional Studies Fatigue Female Humans Lupus Erythematosus, Systemic - blood Male Middle Aged Treatment Outcome Vitamin D - analogs & derivatives |
Title | Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Facr.20186 https://www.ncbi.nlm.nih.gov/pubmed/20235208 https://www.proquest.com/docview/748940893 |
Volume | 62 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3LS91AFIcHcSFu-rKP24ccpIsujE5mJpPErkQrItiFVLiLQphnuXjNFXNTaP3nnZNJIvYB4iohzAzJPH-ZOec7hHykQSQL9MbJhKeJ0KlNSmNZYrXIWO64khb9nU-_yuNzcTLNpivk8-ALE_kQ44YbjoxuvsYBrnSzewcNVQZxnmmBuO2US-TmH56xcX8FOXFFF0gMF7VESDEdwEKU7Y6Z7y9Hf2nM-5K1W3OOnpLvw9tGU5OLnXapd8zvP0COj_ycZ-RJr0VhP3ae52TF1S_I2ml_2r5BbqLrQQOzGn7OluoyXA9hjmZG3bOeydoAbuZCZELPDMzbq7YBd_0rAmEXTdvsQaQkN7CowYdsP1q3Df3hEKBvBYaw2AZVW7DqMsxxL8n50ZdvB8dJH6whMUGTySQXkmutfe4o-g9RadPcS-uo4qXztshLw6UW2igpvTaOea_SIshLz22ZCctfkdV6Ubs3BIwNslBLxMTwMI8zxfNSUcfCv02Waqcn5NPQZpXpSeYYUGNeRQYzq0JlVl1lTsjWmPQq4jv-lQiGhq_C4MITE1W7RdtUiOYRNEi6CXkdO8RYCoadzxgtwst0zfr_4qv9g7Pu5u3Dk74j69FMAS0N35PV5XXrPgT1s9SbXTe_BSmGAKk |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFH4qRQIu7MuwWogDh6Z1HMdJEJeqUA3Q6aFqpbmgyCsaMc1UzQQJ-PP42UlQWSTEKVH0bDleP7_lewAvqAfJHKNxcu5owlVqkkoblhjFc1bYTAqD8c6zQzE94e_n-XwDXg-xMJEfYlS44coI-zUucFRI7_xkDZUa-TzTUlyCy8E-h5DoiI0aFmSKK0MqMTzWEi8yH6iFKNsZS188kH5DmRdBazh19m_Ax6G90dnk83a3Vtv62y9Ujv_7Qzfheg9HyW6cP7dgwza34cqsN7jfge8x-qAli4Z8WazlqX--IUv0NArfelrWlqA-l0Ra6IUmy-6sa4k9_xo5YVdt174ikSi5JauGOF_sU2e3SG8fIhhegVkstohsDDHy1G9zd-Fk_-3x3jTp8zUk2sMykRRcZEopV1iKIURUmLRwwlgqs8o6UxaVzoTiSkshnNKWOSfT0iNMl5kq5ya7B5vNqrEPgGjjkaESyBST-a2cyayoJLXMX2_yVFk1gZfDoNW6JzPHnBrLOtIws9p3Zh06cwLPR9GzyODxJyEyjHzt1xcaTWRjV11bIzsPpx7VTeB-nBFjLZh5Pme09I0J4_r36uvdvaPw8vDfRZ_B1enx7KA-eHf44RFci14L6Hj4GDbX55194sHQWj0Nc_4HLjwExw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3ba9RAFIcPtYXii1qv63UQH3xo2slkMkn0qbRdamuLFAv7IIS5yuI2uzQbwfafd04miVQtiE8JYWZI5vrLzDnfAXhDvUjm6I2TckcjrmITFdqwyCiesswmUhj0dz4-EQdn_HCSTlbgfe8LE_gQw4Ybjox2vsYBvjBu-xc0VGrEeca5uAVrXPhlEhXRKRs2WBAUl7eRxHBVi7jgk54sRNn2kPv6evSHyLyuWdtFZ3wXvvSvG2xNvm01S7WlL38jOf7n99yDO50YJTuh92zAiq3uw_pxd9z-AK6C70FNphX5Pl3Kc3_dIzO0M2qfdVDWmuBuLglQ6Kkms2bR1MRe_AhE2Hnd1O9IwCTXZF4R57N9bewm6U6HCDpXYAyLTSIrQ4w895PcQzgb73_ePYi6aA2R9qJMRBkXiVLKZZaiAxEVJs6cMJbKpLDO5FmhE6G40lIIp7Rlzsk49_rSJaZIuUkewWo1r-wTINp4XagEcmISP5EzmWSFpJb5n5s0VlaN4G3fZqXuUOYYUWNWBggzK31llm1ljuD1kHQR-B1_S0T6hi_96MIjE1nZeVOXyObh1Gu6ETwOHWIoBePOp4zm_mXaZr25-HJn97S9efrvSV_B-qe9cfnxw8nRM7gdTBbQ6vA5rC4vGvvCK6Gletn2-J8kLAN2 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Changes+in+vitamin+D+levels+in+patients+with+systemic+lupus+erythematosus%3A+Effects+on+fatigue%2C+disease+activity%2C+and+damage&rft.jtitle=Arthritis+care+%26+research+%282010%29&rft.au=Ruiz%E2%80%90Irastorza%2C+Guillermo&rft.au=Gordo%2C+Susana&rft.au=Olivares%2C+Nerea&rft.au=Egurbide%2C+Maria%E2%80%90Victoria&rft.date=2010-08-01&rft.issn=2151-464X&rft.eissn=2151-4658&rft.volume=62&rft.issue=8&rft.spage=1160&rft.epage=1165&rft_id=info:doi/10.1002%2Facr.20186&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_acr_20186 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2151-464X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2151-464X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2151-464X&client=summon |